Mgr. Šárka Pavlová, Ph.D.

Assistant professor, Department of Internal Medicine, Hematology and Oncology

correspondence Address:
Jihlavská 340/20, 625 00 Brno

office: bldg. E35/258
Kamenice 753/5
625 00 Brno

phone:	+420 549 49 5442
e‑mail:

social and academic networks:

Basic information

Supervision

Qualifications

Publications

Type

Total number of publications: 197

2018

Evolution of genomic abnormalities during leukemia disease course is associated with telomere length changes

OLBERTOVÁ Helena PLEVOVÁ Karla MALČÍKOVÁ Jitka PAVLOVÁ Šárka POSPÍŠILOVÁ Šárka

Conference abstract

Year: 2018, type: Conference abstract
Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia

PLEŠINGEROVÁ Hana JANOVSKÁ Pavlína MISHRA Ashish Kumar SMYČKOVÁ Lucie POPPOVÁ Lucie LIBRA A. PLEVOVÁ Karla OVESNÁ Petra RADOVÁ Lenka DOUBEK Michael PAVLOVÁ Šárka POSPÍŠILOVÁ Šárka BRYJA Vítězslav

Article in Periodical

Haematologica/the hematology journal, year: 2018, volume: 103, edition: 2, DOI
Genetické aberace a doba do progrese onemocnění u pacientů s CLL léčených režimy FCR nebo BR v 1. linii

ŠPUNAROVÁ Michaela PAVLOVÁ Šárka TOM Nikola BORSKÝ Marek BRYCHTOVÁ Yvona DOUBEK Michael PANOVSKÁ Anna SKUHROVÁ FRANCOVÁ Hana BRZOBOHATÁ Andrea FREIBERGEROVÁ Anna MRÁZ Marek POSPÍŠILOVÁ Šárka MAYER Jiří TRBUŠEK Martin

Conference abstract

Year: 2018, type: Conference abstract
Changes in telomere length associate with to evolution of genomic abnormalities during CLL disease course

OLBERTOVÁ Helena PLEVOVÁ Karla MALČÍKOVÁ Jitka PAVLOVÁ Šárka NAVRKALOVÁ Veronika BRYCHTOVÁ Yvona DOUBEK Michael POSPÍŠILOVÁ Šárka

Conference abstract

Year: 2018, type: Conference abstract
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status

KUBEŠOVÁ Blanka PAVLOVÁ Šárka MALČÍKOVÁ Jitka KABÁTHOVÁ Jitka RADOVÁ Lenka TOM Nikola TICHÝ Boris PLEVOVÁ Karla KANTOROVÁ Barbara FIEDOROVÁ Kristýna SLAVIKOVA M. BYSTRÝ Vojtěch KISSOVÁ Jarmila GISSLINGER B. GISSLINGER H. PENKA Miroslav MAYER Jiří KRALOVICS R. POSPÍŠILOVÁ Šárka DOUBEK Michael

Article in Periodical

Leukemia, year: 2018, volume: 32, edition: 2, DOI
Methodological considerations – TP53 aberrations

PAVLOVÁ Šárka

Requested lectures

Year: 2018, type: Requested lectures
Promoter methylation of ROR1 ligand WNT5A associates with its expression in CLL

POPPOVÁ Lucie JANOVSKÁ Pavlína GONZALEZ B. PLEVOVÁ Karla BYSTRÝ Vojtěch PÁL Karol PLEŠINGEROVÁ Hana BORSKÝ Marek KOTAŠKOVÁ Jana DUMBOVIC G. BIAYNA J. MORENO JM. MORALEDA CM JANSEN S. BRYCHTOVÁ Yvona DOUBEK Michael PAVLOVÁ Šárka ALONSO S. BRYJA Vítězslav POSPÍŠILOVÁ Šárka

Conference abstract

Year: 2018, type: Conference abstract
Somatické mutace TP53 u chronické lymfocytární leukémie: na cestě od malých klonů k chemorezistentnímu onemocnění

PAVLOVÁ Šárka MALČÍKOVÁ Jitka POSPÍŠILOVÁ Šárka

Conference abstract

Year: 2018, type: Conference abstract
ToTem: a tool for variant calling pipeline optimization

TOM Nikola TOM O. MALČÍKOVÁ Jitka PAVLOVÁ Šárka KUBEŠOVÁ Blanka RAUSCH T. KOLARIK M. BENES V. BYSTRÝ Vojtěch POSPÍŠILOVÁ Šárka

Article in Periodical

BMC Bioinformatics, year: 2018, volume: 19, edition: JUN, DOI
Transposable elements in hematological malignancies

VOLAKHAVA Anastasiya PLEVOVÁ Karla PAVLOVÁ Šárka PÁL Karol DARZENTAS Nikos MAMEDOV Ilgar POSPÍŠILOVÁ Šárka

Conference abstract

Year: 2018, type: Conference abstract

Projects

Teaching

10 reasons why you will fall in love with MU

Ask our ambassador

Read about research at MU

Mgr. Šárka Pavlová, Ph.D.

2018

Evolution of genomic abnormalities during leukemia disease course is associated with telomere length changes

Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia

Genetické aberace a doba do progrese onemocnění u pacientů s CLL léčených režimy FCR nebo BR v 1. linii

Changes in telomere length associate with to evolution of genomic abnormalities during CLL disease course

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status

Methodological considerations – TP53 aberrations

Promoter methylation of ROR1 ligand WNT5A associates with its expression in CLL

Somatické mutace TP53 u chronické lymfocytární leukémie: na cestě od malých klonů k chemorezistentnímu onemocnění

ToTem: a tool for variant calling pipeline optimization

Transposable elements in hematological malignancies